Kezdőlap・Részvénylista・Ovid therapeutics Inc

Ovid therapeutics Inc

Lezárt

SzektorEgészségügy

2.91 3.56

Vétel Eladás

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

2.65

Maximum

2.84

Fő mutatók
By Trading Economics
Bevétel	2M -15M
Értékesítés	733K 733K
Egy részvényre jutó nyereség	-0.08
Profit margin	-2,047.476
Munkavállalók	23
EBITDA	566K -16M

Ajánlások
By TipRanks
Ajánlások	Erős vétel
12 hónapos előrejelzés	+121.63% upside

Osztalékok
By Acuity
Következő eredményjelentés	2026. nov. 11.

Piaci statisztika
By TradingEconomics
Piaci kapitalizáció	50M 539M
Előző nyitás	-0.65
Előző zárás	2.91

Hangulat hírek alapján

By Acuity

50%

150 / 340 Rangsor szerint Healthcare

Ovid therapeutics Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. aug. 24. 19:16 UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

2026. aug. 21. 19:46 UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

2026. aug. 20. 23:31 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

2026. aug. 19. 21:21 UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

2026. aug. 14. 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

2026. aug. 13. 19:16 UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

2026. aug. 12. 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

2026. aug. 7. 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

2026. aug. 6. 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

2026. aug. 5. 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

2026. aug. 4. 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

2026. aug. 3. 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

2026. júl. 31. 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

2026. júl. 27. 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

2026. júl. 22. 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

2026. júl. 20. 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Társak összehasonlítása

Árváltozás

Ovid therapeutics Inc Előrejelzés

Célár

By TipRanks

121.63% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 6.25 USD 121.63%

Magas 9 USD

Alacsony 4 USD

6 Wall Street elemző 12 hónapos célárain alapulva a(z)Ovid therapeutics Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

6 ratings

Vétel

Tartás

Eladás

6 Wall Street elemző célárain alapulva a(z)Ovid therapeutics Inc termékhez az elmúlt 3 hónapban.

Hangulat

By Acuity

150 / 340 Rangsor szerint Egészségügy

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

Rólunk Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.